Article

Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer

2024-05-23

Abstract excerpt

<h4>Background</h4> Improving survival for patients diagnosed with metastatic disease and overcoming chemoresistance remain significant clinical challenges in treating breast cancer. Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by a lack of therapeutically targetable receptors (ER/PR/HER2). TNBC therapy includes a combination of cytotoxic chemotherapies, including microtubule-target...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4d1b5185-e77f-52ae-b092-b5d223c11efc
DOI: 10.1101/2024.05.22.595349

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancerDOI 10.1101/2024.05.22.595349Read

A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane ResistanceSemantic proximity Read

A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancerSemantic proximity Read

CLM296: a highly selective inhibitor targeting ALDH1A3-driven tumor growth and metastasis in breast cancerSemantic proximity Read

PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of TubulinSemantic proximity Read

Repurposing mebendazole against triple-negative breast cancer leptomeningeal diseaseSemantic proximity Read

From Virtual Screening to Cell Phenotype: 4-Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer.Semantic proximity Read

Thiosemicarbazone T2 suppresses WNT/β-catenin signaling and limits progression to invasive disease in a mouse intraductal model of triple-negative breast cancerSemantic proximity Read

Biotherapeutic potential and mechanisms of action of colchicineSemantic proximity Read

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.Semantic proximity Read

Class III β-tubulin expression and in vitro resistance to microtubule targeting agentsSemantic proximity Read

Enhanced Anti-Tumor Effects by Combination of Tucatinib and Radiation in HER2-Overexpressing Human Cancer Cell LinesSemantic proximity Read

Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine DerivativesSemantic proximity Read